Global Network

Dow Venture Capital is a Limited Partner in institutional venture capital funds in the US, Europe, Canada and Japan. We work closely with these funds, sharing mutual dealflow, due diligence, and often side-by-side investments. Some of these funds are listed below.

Company	Investment Focus
Advent Venture Partners	Advent invests in early-stage and expansion stage technology companies. Sector focus includes information and communications technologies including software, telecomms, electronics and photonics; and life sciences including biopharmaceuticals, medical devices and platform technologies.
ARCH Venture Partners	ARCH Venture Partners invests in the development of seed and early stage technology companies that focus on innovations in information technology, life sciences, and physical sciences.
Ascent Venture Partners	Ascent Venture Partners invests primarily in technology companies located in the Northeastern United States focusing particularly in technology serving the infrastructure of the Internet.
CMEA Ventures	CMEA Ventures currently has 5 funds and specializes in high technology and life sciences investments. They invest in both early and late stage companies.
Global Catalyst Partners	Global Catalyst Partners focuses on seed and early stage investments in information technologies.
Global Venture Capital	GVC invests primarily in startup companies in Japan but also considers selected opportunities outside of Japan and in later stage companies. The emphasis of investments is in telecommunications, information technology, environmental products and services, healthcare products and services, and advanced materials.
Greenstone Venture Partners	Greenstone Venture Partners focuses on seed and early stage investments in communications and information technologies.
Nth Power	Nth Power focuses on Distributed Energy, Power Reliability, Energy Intelligence, and Related Services with an emphasis on diversification of risk across market sectors and stage of development.
NewPath	NewPath is a venture capital fund focused on the creation of Indo-US companies with US parents and Indian subsidiaries.   The fund’s primary area of expertise is in Information Technology and they are diversifying into the Life Sciences space.
Pitango	Pitango Venture Capital invests in seed, early and expansion stage companies, usually as a lead investor.  Target sectors include communications, enterprise software and internet infrastructure, network and storage, wireless and mobile and life sciences, including medical devices, medical equipment, telemedicine applications and biotech drug delivery.
Prelude (DFJ Esprit Capital Partners)	Prelude Trust is a publicly quoted investment trust which specializes in building technology companies from seed and early-stage.  Prelude invests in sectors that include information technology, communications, advanced materials, sensors, displays and semiconductors. Life science investments include healthcare, drug discovery and medical devices companies.
Sustainable Asset Management (SAM)	SAM invests in the Cleantech sectors, namely, energy, materials, water, and agricultural technologies.
Sofinnova Partners	Sofinnova provides seed, start-up and early stage capital to young technology companies in the information technology and life sciences sectors. Specific focus includes materials, photonics, micro-electronics and software; and therapeutics in both biopharmaceuticals and medical devices.
Technology Partners	Technology Partners teams with visionary entrepreneurs to build successful new companies. We serve principally as a lead investor and business advisor to both Life Science and Cleantech companies.
TechnoStart	TechnoStart specializes in funding and developing seed and early stage technology companies, primarily in Germany, in the fields of applied physics, life sciences, chemistry and new materials.
Techno Venture Management (TVM)	TVM LifeSciences invests in later stage and earlier stage companies involved in drug discovery and development. Later stage is defined as having products in clinical trials. Specific focus includes proteins, peptides and small molecules; cell-based therapy;  gene- and immunotherapy; and drug delivery and specialty pharmaceuticals.
Watervein	Watervein invests in the development of seed and early stage technology companies that focus on innovations in life sciences in Japan.

Through these global activities, we have developed a wide-reaching network of other investors and entrepreneurs who are pursuing activities in markets and technologies which complement our own.  We bring this wide collective experience to the successful development of our portfolio companies.